Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.

Früh, M.; Panje, C.M.; Reck, M; Blackhall, F; Califano, R; Cappuzzo, F; Besse, B; Novello, S; Garrido, P; Felip, E; O'Brien, M; Paz Ares, L; de Marinis, F; Westeel, V; De Ruysscher, D; Putora, P.M. (2020). Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung cancer, 146, pp. 6-11. Elsevier 10.1016/j.lungcan.2020.03.024

[img] Text
1-s2.0-S0169500220303548-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (780kB) | Request a copy

OBJECTIVES

Stage IV small cell lung cancer (SCLC) is associated with short survival and progression after first-line systemic therapy frequently occurs within months. Although topotecan is approved for second-line treatment, its efficacy is limited, and treatment heterogeneity exists.

MATERIAL AND METHODS

The decision-making patterns for second line treatment of 13 European medical oncologists with expertise in SCLC were analyzed.

RESULTS

The two criteria most relevant to decision-making were the performance status and the interval of recurrence since first-line treatment. With an interval of less than 3 months since the end of first-line chemotherapy, 62 % of the experts recommended cyclophosphamide, doxorubicin and vincristine (CAV) for fit patients and 54 % recommended topotecan for unfit patients. For an interval of more than 6 months, a clear consensus for a re-challenge with a platinum doublet was achieved (92 %). However, there was no consensus on the second-line therapy with an interval of 3-6 months since the end of first-line therapy.

CONCLUSION

Real world practice may differ from recommendations in general guidelines and cannot always be directly derived from trial results as other factor such as habits, patient's preference, convenience or costs have to be factored in.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Früh, Martin; Panje, Cédric and Putora, Paul Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0169-5002

Publisher:

Elsevier

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

24 Jun 2020 17:39

Last Modified:

07 Jun 2021 14:02

Publisher DOI:

10.1016/j.lungcan.2020.03.024

PubMed ID:

32485661

Uncontrolled Keywords:

Decision making Objective consensus Second-line chemotherapy Small cell lung cancer (SCLC)

BORIS DOI:

10.7892/boris.144508

URI:

https://boris.unibe.ch/id/eprint/144508

Actions (login required)

Edit item Edit item
Provide Feedback